A multicenter randomized double-blind placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of house dust mite (Dermatophagoides pteronyssinus) in patients with allergic bronchial asthma and with allergic rhinitis or rhinoconjunctivitis

Trial Profile

A multicenter randomized double-blind placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of house dust mite (Dermatophagoides pteronyssinus) in patients with allergic bronchial asthma and with allergic rhinitis or rhinoconjunctivitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergopharma
  • Most Recent Events

    • 23 Dec 2017 Planned number of patients changed from 446 to 1390.
    • 26 Oct 2017 Planned End Date changed from 23 Apr 2021 to 23 Apr 2019.
    • 16 Sep 2017 Planned number of patients changed from 444 to 446.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top